When Oncology NDAs Fail, Clinical Benefit Is Often In Question
This article was originally published in The Pink Sheet Daily
Executive Summary
Pre-submission meetings can address questions of clinically meaningful endpoints and appropriate subgroups, avoiding negative regulatory outcomes, FDA analysis suggests.